Related Experiment Videos
Studies on phenotypic expression patterns of proteases and protease inhibitors in benign compared to malignant
A Bjartell1, A Paju, U H Stenman
1Department of Urology, Malmö University Hospital, Sweden.
Prostate Cancer and Prostatic Diseases
|December 24, 2002
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Imaging modalities in advanced prostate cancer: Interim analysis of the Spanish cohort of the RING registry.
Actas urologicas espanolas·2026
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2023
Risk of hernia formation after radical prostatectomy: a comparison between open and robot-assisted laparoscopic radical prostatectomy within the prospectively controlled LAPPRO trial.
Hernia : the journal of hernias and abdominal wall surgery·2020
Oncological and functional outcomes of focal irreversible electroporation for localised prostate cancer: a single institution series of 171 cases.
Prostate cancer and prostatic diseases·2026
Correlation of intraprostatic lesional SUVmax during PSMA PET/CT and adverse pathology at radical prostatectomy.
Prostate cancer and prostatic diseases·2026
Prostate size and its effect on sexual function following convective water vapor thermal therapy.
Prostate cancer and prostatic diseases·2026
Successful cabazitaxel desensitization after severe taxane hypersensitivity reactions: a brief report.
Prostate cancer and prostatic diseases·2026
Utilization patterns of second-generation androgen receptor pathway inhibitors as first-line therapy for prostate cancer in the United States.
Prostate cancer and prostatic diseases·2026
From fungus fighter to cancer slayer: itraconazole as a multifaceted candidate for drug-resistant prostate cancer.
Prostate cancer and prostatic diseases·2026